In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

CTCAE Skin Toxicity

CTCAE v5.0 (Skin): Standardized classification of oncology-related adverse events.

Select Severity Level

Awaiting Grade

Select the description that best matches the severity of the skin reaction to determine the clinical CTCAE grade.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

The Common Terminology Criteria for Adverse Events (CTCAE) is the standard vocabulary used by the National Cancer Institute (NCI) and the oncology community to report adverse events in clinical trials and routine care. The Skin and Subcutaneous Tissue Disorders category provides specific grading criteria for dermatologic toxicities associated with chemotherapy, targeted therapy, immunotherapy, and radiation.

Indications

Grading severity of dermatologic adverse events from antineoplastic therapies

Determining whether to hold, dose-reduce, or discontinue oncology drugs

Reporting toxicities in clinical trials (mandatory protocol requirement)

Standardizing communication between dermatology and oncology teams

When NOT to Use

Primary non-drug-induced dermatologic conditions (e.g., standard psoriasis, atopic dermatitis) — use PASI, EASI, BSA

When evaluating drug causality (use ALDEN or Naranjo algorithm for causality; CTCAE only grades severity)

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the SCORTEN, AGEP Score or the ALDEN Algorithm to formulate a comprehensive care plan.

Last Comprehensive Review: 2026